Table 2.

Adjusted incidence rate ratio of any AESI after BNT162b2 and CoronaVac vaccines using modified SCCS

Period	Events	Follow-up time, person-years	IRR (95% CI)	P value	Events	Follow-up time, person-years	IRR (95% CI)	P value
	BNT162b2				CoronaVac
Baseline	13,948	15,262.14	—	—	17,331	18,842.38	—	—
Day 0 after first dose	2	7.09	—	—	0	16.92	—	—
Days 1–13 after first dose	44	89.42	0.65 (0.46–0.90)	0.010	124	213.45	0.67 (0.54–0.84)	0.001
Days 14–27 after first dose	56	58.95	1.20 (0.90–1.59)	0.211	131	204.12	0.82 (0.66–1.02)	0.074
Days 1–27 after first dose	100	148.37	0.86 (0.69–1.08)	0.207	255	417.57	0.76 (0.64–0.91)	0.002
Day 0 after second dose	2	5.60	—	—	2	10.85	—	—
Days 1–13 after second dose	41	68.26	0.84 (0.61–1.16)	0.290	84	122.85	0.84 (0.64–1.10)	0.205
Days 14–27 after second dose	54	62.72	1.15 (0.86–1.53)	0.344	70	96.68	0.83 (0.63–1.07)	0.154
Days 1–27 after second dose	95	130.98	0.96 (0.76–1.22)	0.757	154	219.52	0.86 (0.71–1.05)	0.141
Day 0 after third dose	0	1.56	—	—	0	1.59	—	—
Days 1–13 after third dose	8	17.91	0.58 (0.26–1.29)	0.181	7	18.36	0.73 (0.29–1.82)	0.498
Days 14–27 after third dose	8	14.37	0.70 (0.32–1.53)	0.370	6	14.23	0.66 (0.27–1.62)	0.362
Days 1–27 after third dose	16	32.29	0.60 (0.33–1.10)	0.101	13	32.59	0.74 (0.36–1.54)	0.424

AESI, adverse event of special interest; CI, confidence interval; IRR, incidence rate ratio; SCCS, self-controlled case series.